Medical devices, healthcare technology and the business of care
PMA approval · P240011

Medtronic Altaviva System

Medtronic Neuromodulation · Decision date Sep 18, 2025

MEDTECHLEDGER EXPLANATIONP240011

What did the FDA approve?

FDA approved the Medtronic Altaviva System on September 18, 2025. The approval statement describes the device as indicated for treatment of urge urinary incontinence in patients who failed or could not tolerate more conservative treatments.

The database lists the product code QPT and device category as an implantable tibial electrical stimulator for urinary incontinence. The specialty field includes gastroenterology and urology. The statement does not include safety or effectiveness data, and the record does not identify this decision as a supplement.

FDA approval order statement

Approval for the Medtronic Altaviva System is indicated for treatment of urge urinary incontinence (UUI) in patients who failed or could not tolerate more conservative treatments.
Regulatory pathway
Original PMA
Clinical specialty
Gastroenterology, Urology
Decision date
Sep 18, 2025

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P240011
Regulatory pathway
Premarket approval application
Product code
QPT
Decision code
APPR
Decision date
Sep 18, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, tibial, electrical, implantable, for urinary incontinence.

Product code
QPT
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P240011 received

    Application receipt date recorded by FDA.

  2. P240011 · FDA decision

    APPR

  3. P240011/S001 · Related supplement

    Altaviva Implantable Neurostimulator

  4. P240011/S002 · Related supplement

    Altaviva Implantable Neurostimulator

  5. P240011/S004 · Related supplement

    Medtronic Altaviva System

  6. P240011/S007 · Related supplement

    Altaviva Tibial Neuromodulation System (Altaviva P7850N)

Timeline entries are records held by MedtechLedger for P240011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240011

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic NeuromodulationPMA supplementOct 17, 2025FDA
Medtronic NeuromodulationPMA supplementOct 21, 2025FDA
AltavivaP240011/S003
Medtronic NeuromodulationPMA supplementNov 26, 2025FDA
Medtronic NeuromodulationPMA supplementDec 19, 2025FDA
AltavivaP240011/S005
Medtronic NeuromodulationPMA supplementJan 14, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 6, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 12, 2026FDA
AltavivaP240011/S008
Medtronic NeuromodulationPMA supplementFeb 27, 2026FDA
AltavivaP240011/S011
Medtronic NeuromodulationPMA supplementMar 26, 2026FDA
AltavivaP240011/S012
Medtronic NeuromodulationPMA supplementApr 3, 2026FDA
AltavivaP240011/S013
Medtronic NeuromodulationPMA supplementMay 13, 2026FDA
AltavivaP240011/S014
Medtronic NeuromodulationPMA supplementJun 16, 2026FDA
AltavivaP240011/S010
Medtronic NeuromodulationPMA supplementJul 13, 2026FDA
AltavivaP240011/S015
Medtronic NeuromodulationPMA supplementAug 14, 2026FDA
AltavivaP240011/S016
Medtronic NeuromodulationPMA supplementSep 14, 2026FDA

Explore the linked device profile

Other records with product code QPT

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA supplementSep 9, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementJul 20, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementMar 3, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic Neuromodulation

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
7000 Central Ave. NE, Ms Rce480, Minneapolis, MN, 55432

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records